Thailand Expands Access to Risdiplam for Universal Healthcare Patients
The National Health Security Office (NHSO) board has approved the inclusion of Risdiplam in the National List of Essential Medicines, securing three years of funding for eligible patients.
On October 8, 2026, Matichon Online reported that the National Health Security Office (NHSO) board officially approved the inclusion of Risdiplam into the National List of Essential Medicines. This decision is accompanied by a commitment to provide continuous funding for the medication over the next three years.
Risdiplam is a critical treatment used for patients suffering from Spinal Muscular Atrophy (SMA). By adding this drug to the essential medicines list, the NHSO aims to significantly improve access to life-saving therapy for individuals covered under Thailand’s universal healthcare scheme, commonly known as the 'Gold Card' system.
For residents and expatriates enrolled in the Thai universal healthcare system, this development represents a major step in expanding the scope of specialized treatments covered by the state. It ensures that patients requiring this specific medication will have a more reliable pathway to treatment without the prohibitive costs previously associated with such rare disease therapies.
While the board has approved the inclusion and the three-year budget, specific details regarding the rollout timeline, the exact criteria for patient eligibility, and the logistics of distribution at participating hospitals remain to be confirmed. Patients are advised to consult with their primary healthcare providers or local NHSO representatives for updates on how this policy change may affect their specific treatment plans.
